معرفی
Andrew Spillane is Professor of Surgical Oncology at The University of Sydney's Northern Clinical School, with clinical appointments at Mater North Sydney, Royal North Shore, and North Shore Private Hospitals. He specializes in melanoma and breast cancer surgery and chairs the Clinical Committee at Melanoma Institute Australia (MIA). His executive roles include leadership in the Australian and New Zealand Melanoma Trials Group (ANZMTG) and past presidency of Breast Surgeons of Australia and New Zealand.
His research investigates surgical quality assurance, clinical trial methodologies, and translational oncology. Key projects include the international MelMART-2 trial (surgical margins for melanoma) and EAGLE FM (management of metastatic melanoma in groin nodes). He co-directs the University of Sydney's Graduate Certificate in Breast Surgery and teaches oncoplastic techniques internationally.
Research trends from his publications focus on:
- Optimizing surgical outcomes in melanoma/breast cancer
- Neoadjuvant therapy response biomarkers
- Risk-prediction model development
- Cost-effectiveness of surgical interventions
- Surveillance protocols for node-positive patients
Awards:
- BreastSurgANZ Lecture 2018
He leads multidisciplinary teams at MIA and supervises Training Fellows in Surgical Oncology. His work emphasizes integrating clinical research with surgical education and guideline development (e.g., Cancer Council Australia Melanoma Guidelines).